Evidence map›Paper›PMID 38063387›Full record

ArticleMicrobiology spectrum2024

Pharmacokinetic/pharmacodynamic analysis of ceftazidime/avibactam and fosfomycin combinations in an

Niklas Kroemer, Lisa F Amann, Aneeq Farooq, Christoph Pfaffendorf, Miklas Martens, Jean-Winoc Decousser, Nicolas Grégoire, Patrice Nordmann, Sebastian G Wicha

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Increased Prevalence of Multidrug-ResistantLife (Basel, Switzerland) · 2026
    Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Niklas KroemerInstitute of Pharmacy, University of Hamburg , Hamburg, Germany.ORCID 0000-0002-6941-1647
Lisa F AmannInstitute of Pharmacy, University of Hamburg , Hamburg, Germany.ORCID 0000-0002-1274-9276
Aneeq FarooqInstitute of Pharmacy, University of Hamburg , Hamburg, Germany.
Christoph PfaffendorfInstitute of Pharmacy, University of Hamburg , Hamburg, Germany.
Miklas MartensInstitute of Pharmacy, University of Hamburg , Hamburg, Germany.
Jean-Winoc DecousserDynamic Team - EA 7380, Faculté de Santé, Université Paris-Est-Créteil Val-De-Marne , Créteil, France.ORCID 0000-0001-7105-6202
Nicolas GrégoireInserm U1070 , Poitiers, France.ORCID 0000-0001-6436-3757
Patrice NordmannMedical and Molecular Microbiology, University of Fribourg , Fribourg, Switzerland.ORCID 0000-0002-1343-1622
Sebastian G WichaInstitute of Pharmacy, University of Hamburg , Hamburg, Germany.ORCID 0000-0002-8773-4845
Universität Hamburg · DEInserm · FRUniversité Paris-Est Créteil · FRUniversity of Fribourg · CH

Funding

Agence Nationale de la Recherche (ANR) R19094GGBundesministerium für Bildung und Forschung (BMBF) 16GW0249K
6 · The paper itself

Abstract

importanceMechanistic understanding of pharmacodynamic interactions is key for the development of rational antibiotic combination therapies to increase efficacy and suppress the development of resistances. Potent tools to provide those insights into pharmacodynamic drug interactions are semi-mechanistic modeling and simulation techniques. This study uses those techniques to provide a detailed understanding with regard to the direction and strength of the synergy of ceftazidime-avibactam and ceftazidime-fosfomycin in a clinical

Indexed as

Azabicyclo CompoundsCeftazidimeFosfomycinAnti-Bacterial Agentsbeta-LactamasesDrug CombinationsEscherichia coliMicrobial Sensitivity TestsAnti-Bacterial Agentsavibactamavibactam, ceftazidime drug combinationAzabicyclo Compoundsbeta-LactamasesCeftazidimeDrug CombinationsFosfomycinceftazidime/avibactamdrug interactionsEscherichia colifosfomycinhollow fiber infection modelPK/PDsynergy

Identifiers

PMID38063387
PMCPMC10783110
OpenAlexW4389488582

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.